LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
| Autor: | Prat, A., Falato, C., Pare Brunet, L., Martinez Saez, O., Cejalvo Andujar, J.M., Margeli Vila, M., Tolosa, P., Salvador Bofill, F.J., Cruz Jurado, J., Gonzalez-Farre, B., Sanfeliu Torres, E., Ciruelos, E.M., Espinosa-Bravo, M., Izarzugaza Peron, Y., Pernas Simon, S., Esker, S., Fan, P-D., Ferrero Cafiero, J.M., Pascual, T., Oliveira, M. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S164-S164 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|